EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer

Midori Yui, Satoaki Nakamura, Yuhei Koike, Kazuki Hirota, Ken Yoshida, Asami Yoshida, Kenichi Ueda, Ken Shigeyama, Hideki Takegawa, Yusuke Anetai, Masaaki Paku, Takayasu Kurata und 2 weitere

Anticancer Research · 2025

DOI: 10.21873/anticanres.17498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Midori Yui und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Spinal Neoplasms, Molecular Targeted Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The effect of modern molecular-targeted agents (MTAs), on vertebral metastases in non-small cell lung cancer (NSCLC) remains inadequately characterized. We investigated the local control effects of MTAs on vertebral metastases in patients with NSCLC. PATIENTS AND METHODS: We retrospectively analyzed 307 vertebral metastases in 85 patients with NSCLC, treated between 2019 and 2021. Patients were categorized based on prior systemic therapy exposure (19 with vs. 66 without) and the type of first-line therapy administered (32 MTA vs. 34 non-MTAs). Multivariate analyses were performed for the vertebral progression-free period (vPFP) and overall survival (OS) using a Cox proportional hazards model with propensity scores as covariates. p-Value correction for multiple pairwise comparisons was performed using the Bonferroni method. RESULTS: In treatment-naïve patients, MTAs presented superior outcomes compared with non-MTAs [1-year vPFP: 93.6% vs. 85.1%, p=0.02; 1-year overall survival (OS): 90.3% vs. 60.9%, p=0.004]. Patients without prior systemic therapy had significantly better outcomes than previously treated patients (1-year vPFP: 89.5% vs. 49.1%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSpinal NeoplasmsMolecular Targeted TherapyHumansFemaleMaleAgedMiddle AgedRetrospective StudiesAged, 80 and overAdultTreatment Outcome

Stichwörter der Autor:innen

Non-small cell lung cancermolecular-targeted therapysystemic therapyvertebral metastasis

Autor:innen und Institutionen

  • Division of Radiation Oncology, Kansai Medical University, Osaka, Japan.
  • Division of Radiation Oncology, Kansai Medical University, Osaka, Japan; kmu@nakamura.pro.
  • Department of Orthopedic Surgery, Kansai Medical University, Osaka, Japan.
  • Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan.
  • Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Radiology, Kansai Medical University, Osaka, Japan.

Zitieren

APA

Yui, M., Nakamura, S., Koike, Y., Hirota, K., Yoshida, K., Yoshida, A., Ueda, K., Shigeyama, K., Takegawa, H., Anetai, Y., Paku, M., Kurata, T., Yamazaki, H., & Tanigawa, N. (2025). Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17498

Vancouver

Yui M, Nakamura S, Koike Y, Hirota K, Yoshida K, Yoshida A, et al. Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer. Anticancer Research. 2025. doi:10.21873/anticanres.17498

BibTeX
@article{Yui2025,
  author = {Yui, Midori and Nakamura, Satoaki and Koike, Yuhei and Hirota, Kazuki and Yoshida, Ken and Yoshida, Asami and Ueda, Kenichi and Shigeyama, Ken and Takegawa, Hideki and Anetai, Yusuke and Paku, Masaaki and Kurata, Takayasu and Yamazaki, Hideya and Tanigawa, Noboru},
  title = {Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17498}
}
Kostenlos starten →